Provided by Tiger Trade Technology Pte. Ltd.

Disc Medicine

74.14
-2.3700-3.10%
Pre-market: 75.000.8600+1.16%07:44 EDT
Volume:480.87K
Turnover:35.82M
Market Cap:2.85B
PE:-11.30
High:76.59
Open:75.89
Low:73.16
Close:76.51
52wk High:99.50
52wk Low:40.00
Shares:38.39M
Float Shares:32.95M
Volume Ratio:1.00
T/O Rate:1.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.5619
EPS(LYR):-6.0116
ROE:-39.08%
ROA:-23.96%
PB:4.42
PE(LYR):-12.33

Loading ...

Disc Medicine COO Jonathan Yen-wen Yu Disposes of 9,700 Common Shares Worth $704,795

Reuters
·
Jun 25

Disc Medicine Stockholders Approve Governance and Executive Pay

TIPRANKS
·
Jun 25

Disc Medicine Shareholders Approve Advisory Executive Pay Vote

Reuters
·
Jun 25

Disc Medicine CEO John Quisel disposes of common shares worth $2.38 million

Reuters
·
Jun 24

Disc Medicine COO Yu Jonathan Yen-Wen sells 18,612 shares for USD 1.29 million

Reuters
·
Jun 19

Disc Medicine (IRON) Stock Could Be 64% Below Fair Value After EHA Trial Update

Simply Wall St.
·
Jun 17

Press Release: LABRADOR IRON ORE ROYALTY CORPORATION - CASH DIVIDEND FOR THE SECOND QUARTER OF 2026 - $0.30 PER COMMON SHARE

Dow Jones
·
Jun 17

Disc Medicine Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Jun 16

Wedbush Sticks to Its Buy Rating for Disc Medicine (IRON)

TIPRANKS
·
Jun 16

Disc Medicine price target raised to $85 from $80 at Morgan Stanley

TIPRANKS
·
Jun 16

Disc Medicine posts corporate deck highlighting bitopertin in EPP pipeline progress

Reuters
·
Jun 16

Disc Medicine says DISC-0974 posts durable anemia responses in Phase 2 RALLY-MF trial in myelofibrosis

Reuters
·
Jun 12

Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting

GlobeNewswire
·
Jun 12

H.C. Wainwright Remains a Buy on Disc Medicine (IRON)

TIPRANKS
·
Jun 11

Disc Medicine Price Target Maintained With a $88.00/Share by Wedbush

Dow Jones
·
Jun 10

Disc Medicine (IRON) Is Down 8.6% After Mixed Trial Success And FDA Setback What's Changed

Simply Wall St.
·
Jun 10

Disc Medicine Buy Rating Reiterated as APOLLO Phase III Progress and Bitopertin Outlook Support Unchanged $100 Price Target

TIPRANKS
·
Jun 09

Disc Medicine - Expects Crl Response Submission by End of 2026

THOMSON REUTERS
·
Jun 09

Disc Medicine - Apollo Study Data Expected Q4 2026; FDA Decision Expected by Mid-2027

THOMSON REUTERS
·
Jun 09

Disc Medicine - FDA Agrees Phase 3 Apollo Study Can Support Crl Response and Potential Approval

THOMSON REUTERS
·
Jun 09